FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308523231> ?p ?o ?g. }

• W4308523231 endingPage "103196" @default.
• W4308523231 startingPage "103196" @default.
• W4308523231 abstract "Cervical intraepithelial neoplasia (CIN) is a precursor lesion of cervical cancer. Traditional treatments for CIN might have negative effects on cervical anatomical structure and physiological function. Topical 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) is a novel, non-invasive targeted therapy for intraepithelial lesions. This study aims to evaluate and compare the efficacy and safety of 5-ALA PDT for different grades of CIN.A retrospective study of 183 patients aged 19-50 with histologically confirmed CIN and receiving ALA-PDT was conducted. ALA-PDT was performed with 20% ALA thermosensitive gel and irradiation at a wavelength of 635 nm and density of 80-100 J/cm2. ALA-PDT was conducted every 7-10 days for 4-6 times. Patients were followed up three, six, nine, and twelve months after treatment. The effect was evaluated through HPV genotyping, ThinPrep cytology test (TCT), and colposcopy-directed biopsy.The HPV clearance rate was 71.0% (130/183) at the six-month follow-up and 84.5% (147/174) at the 12-month follow-up. The complete lesion remission (CR) rate was 90.2% (165/183). No statistically significant differences concerning the CR rate (P>0.05) or HPV clearance rates (P>0.05) were observed in CIN I, CIN II, and CIN III. In women with CIN III, gland involvement was revealed to be associated with a significantly lower HPV clearance rate (63.16% vs. 92.60%, P= 0.036) at the 12-month follow-up. Our study showed that the atypical vessels seemed to be a risk factor for HPV clearance rate in the CIN II group at six-month follow-up, although the difference was not statistically significant (P= 0.089). During the follow-up, 13 cases had persistent lesions (7.1%), four cases recurred (2.3%), and none of the patients progressed. The study also showed that the efficacy of PDT in the treatment of patients with CIN III involving glands was comparable to that of CKC (P>0.05).ALA-PDT is an effective andsafe treatment for CIN, and responseis unaffected by the grade of lesions. However, for patients with atypical vessels and glandular involvement, the effect of PDT seems to be poorer." @default.
• W4308523231 created "2022-11-12" @default.
• W4308523231 creator A5021119678 @default.
• W4308523231 creator A5021678671 @default.
• W4308523231 creator A5029570990 @default.
• W4308523231 creator A5038382395 @default.
• W4308523231 creator A5039978170 @default.
• W4308523231 creator A5040690752 @default.
• W4308523231 creator A5050702240 @default.
• W4308523231 creator A5067505099 @default.
• W4308523231 creator A5068041333 @default.
• W4308523231 creator A5077372450 @default.
• W4308523231 creator A5088174174 @default.
• W4308523231 date "2022-12-01" @default.
• W4308523231 modified "2023-09-29" @default.
• W4308523231 title "The effect of local photodynamic therapy with 5-aminolevulinic acid in treating different grades of cervical intraepithelial neoplasia" @default.
• W4308523231 cites W1862348948 @default.
• W4308523231 cites W1964146509 @default.
• W4308523231 cites W1978279424 @default.
• W4308523231 cites W2000351935 @default.
• W4308523231 cites W2046591921 @default.
• W4308523231 cites W2064871370 @default.
• W4308523231 cites W2071201298 @default.
• W4308523231 cites W2073110480 @default.
• W4308523231 cites W2082506629 @default.
• W4308523231 cites W2157247388 @default.
• W4308523231 cites W2157883975 @default.
• W4308523231 cites W2213210908 @default.
• W4308523231 cites W2664931613 @default.
• W4308523231 cites W2793055923 @default.
• W4308523231 cites W2962527820 @default.
• W4308523231 cites W3010535837 @default.
• W4308523231 cites W3015112546 @default.
• W4308523231 cites W3118909934 @default.
• W4308523231 cites W3128646645 @default.
• W4308523231 cites W3154718361 @default.
• W4308523231 cites W3204203203 @default.
• W4308523231 cites W3216392961 @default.
• W4308523231 cites W4283755742 @default.
• W4308523231 doi "https://doi.org/10.1016/j.pdpdt.2022.103196" @default.
• W4308523231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36368451" @default.
• W4308523231 hasPublicationYear "2022" @default.
• W4308523231 type Work @default.
• W4308523231 citedByCount "1" @default.
• W4308523231 countsByYear W43085232312023 @default.
• W4308523231 crossrefType "journal-article" @default.
• W4308523231 hasAuthorship W4308523231A5021119678 @default.
• W4308523231 hasAuthorship W4308523231A5021678671 @default.
• W4308523231 hasAuthorship W4308523231A5029570990 @default.
• W4308523231 hasAuthorship W4308523231A5038382395 @default.
• W4308523231 hasAuthorship W4308523231A5039978170 @default.
• W4308523231 hasAuthorship W4308523231A5040690752 @default.
• W4308523231 hasAuthorship W4308523231A5050702240 @default.
• W4308523231 hasAuthorship W4308523231A5067505099 @default.
• W4308523231 hasAuthorship W4308523231A5068041333 @default.
• W4308523231 hasAuthorship W4308523231A5077372450 @default.
• W4308523231 hasAuthorship W4308523231A5088174174 @default.
• W4308523231 hasConcept C121608353 @default.
• W4308523231 hasConcept C126322002 @default.
• W4308523231 hasConcept C126894567 @default.
• W4308523231 hasConcept C142724271 @default.
• W4308523231 hasConcept C178790620 @default.
• W4308523231 hasConcept C185592680 @default.
• W4308523231 hasConcept C18823058 @default.
• W4308523231 hasConcept C2775934546 @default.
• W4308523231 hasConcept C2776117191 @default.
• W4308523231 hasConcept C2776235491 @default.
• W4308523231 hasConcept C2777343196 @default.
• W4308523231 hasConcept C2778220009 @default.
• W4308523231 hasConcept C2779534503 @default.
• W4308523231 hasConcept C2781156865 @default.
• W4308523231 hasConcept C2781323092 @default.
• W4308523231 hasConcept C71924100 @default.
• W4308523231 hasConcept C90924648 @default.
• W4308523231 hasConceptScore W4308523231C121608353 @default.
• W4308523231 hasConceptScore W4308523231C126322002 @default.
• W4308523231 hasConceptScore W4308523231C126894567 @default.
• W4308523231 hasConceptScore W4308523231C142724271 @default.
• W4308523231 hasConceptScore W4308523231C178790620 @default.
• W4308523231 hasConceptScore W4308523231C185592680 @default.
• W4308523231 hasConceptScore W4308523231C18823058 @default.
• W4308523231 hasConceptScore W4308523231C2775934546 @default.
• W4308523231 hasConceptScore W4308523231C2776117191 @default.
• W4308523231 hasConceptScore W4308523231C2776235491 @default.
• W4308523231 hasConceptScore W4308523231C2777343196 @default.
• W4308523231 hasConceptScore W4308523231C2778220009 @default.
• W4308523231 hasConceptScore W4308523231C2779534503 @default.
• W4308523231 hasConceptScore W4308523231C2781156865 @default.
• W4308523231 hasConceptScore W4308523231C2781323092 @default.
• W4308523231 hasConceptScore W4308523231C71924100 @default.
• W4308523231 hasConceptScore W4308523231C90924648 @default.
• W4308523231 hasLocation W43085232311 @default.
• W4308523231 hasLocation W43085232312 @default.
• W4308523231 hasOpenAccess W4308523231 @default.
• W4308523231 hasPrimaryLocation W43085232311 @default.
• W4308523231 hasRelatedWork W1964196275 @default.
• W4308523231 hasRelatedWork W2325899766 @default.
• W4308523231 hasRelatedWork W2367464687 @default.

• next